BioSpace News Archive

Weeks after the FDA rejected Veru’s Emergency Use Authorization bid for sabizabulin in COVID-19, the company announced plans to continue with late-stage development of the drug.

After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves.

Some high-profile tech CEOs have recently elected to take large pay cuts to conserve cash flow. This has sparked a larger conversation about how executive compensation is decided.

Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.

Jounce Therapeutics has received an unsolicited and non-binding acquisition proposal from Concentra Biosciences, looking to buy 100% of Jounce’s equity at a per-share price of $1.80 in cash.

Bellicum Pharmaceuticals has ended the only clinical trials evaluating its GoCAR-T cell product in combination with rimiducid following serious safety concerns.

GPCR Therapeutics, Inc., a clinical stage, international biopharmaceutical company focused on targeting G Protein Coupled Receptors pairs, announced publication of a paper in Nature Scientific Reports, in collaboration with the School of Biological Sciences, Seoul National University.

GenSight Biologics announces that efficacy and safety data from patients with Leber Hereditary Optic Neuropathy carrying the ND4 mutation treated with lenadogene nolparvovec through early access programs, were presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society.

While recent advancements in treatment of early-stage Alzheimer’s, including mild cognitive impairment due to Alzheimer’s disease, are providing hope to millions living with memory loss and early cognitive decline, the Alzheimer’s Association 2023 Alzheimer’s Disease Facts and Figures report finds too often individuals with memory concerns and their doctors are not discussing the issue, missing a critical first step toward diagnosis and potential treatment.

InDex Pharmaceuticals Holding AB announced positive results from a pharmacokinetic study with cobitolimod in patients with moderate to severe ulcerative colitis.